^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | anbenitamab (KN026) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Two and a half years follow-up data of HER2-targeted bispecific antibody KN026 combined with docetaxel as first-line treatment for HER2-positive recurrent/metastatic breast cancer.
Published date:
12/02/2023
Excerpt:
The mPFS of 48 subjects with high HER2 expression (3+) was 28.1 months….KN026 in combination with docetaxel is well tolerated and has shown promising clinical benefit as 1L treatment for HER2-positive BC. After 2.5 years follow-up, mPFS was 27.7 mons and the 24-months OS rate was 84.2%, which is very promising.
Secondary therapy:
docetaxel
